Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Precision Biosciences Inc (DTIL)

Precision Biosciences Inc (DTIL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 44,109
  • Shares Outstanding, K 7,671
  • Annual Sales, $ 48,730 K
  • Annual Income, $ -61,320 K
  • EBIT $ 4 M
  • EBITDA $ 12 M
  • 60-Month Beta 1.41
  • Price/Sales 0.94
  • Price/Cash Flow N/A
  • Price/Book 0.66

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.42
  • Number of Estimates 1
  • High Estimate -0.42
  • Low Estimate -0.42
  • Prior Year -3.35
  • Growth Rate Est. (year over year) +87.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.12 +7.42%
on 12/11/24
8.51 -35.37%
on 11/13/24
-2.88 (-34.37%)
since 11/11/24
3-Month
5.12 +7.42%
on 12/11/24
10.71 -48.65%
on 09/12/24
-5.00 (-47.62%)
since 09/11/24
52-Week
5.12 +7.42%
on 12/11/24
19.43 -71.69%
on 02/29/24
-6.17 (-52.87%)
since 12/11/23

Most Recent Stories

More News
Precision BioSciences: Q3 Earnings Snapshot

Precision BioSciences: Q3 Earnings Snapshot

DTIL : 5.50 (-4.35%)
Precision BioSciences: Q2 Earnings Snapshot

Precision BioSciences: Q2 Earnings Snapshot

DTIL : 5.50 (-4.35%)
Incyte, Squarespace rise; Chimera Investment, Amazon fall, Monday, 5/13/2024

Stocks that traded heavily or had substantial price changes on Monday: Incyte, Squarespace rise; Chimera Investment, Amazon fall

AMZN : 229.54 (+2.00%)
DTIL : 5.50 (-4.35%)
CIM : 14.97 (-1.12%)
INTC : 20.10 (-0.30%)
WBA : 9.73 (-6.62%)
TME : 11.85 (-5.20%)
INCY : 72.76 (+0.39%)
Precision BioSciences: Q1 Earnings Snapshot

Precision BioSciences: Q1 Earnings Snapshot

DTIL : 5.50 (-4.35%)
Precision BioSciences: Q4 Earnings Snapshot

Precision BioSciences: Q4 Earnings Snapshot

DTIL : 5.50 (-4.35%)
Precision BioSciences: Q3 Earnings Snapshot

Precision BioSciences: Q3 Earnings Snapshot

DTIL : 5.50 (-4.35%)
Precision BioSciences: Q2 Earnings Snapshot

Precision BioSciences: Q2 Earnings Snapshot

DTIL : 5.50 (-4.35%)
Precision BioSciences: Q1 Earnings Snapshot

Precision BioSciences: Q1 Earnings Snapshot

DTIL : 5.50 (-4.35%)
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that, on April...

DTIL : 5.50 (-4.35%)
Precision BioSciences to Report First Quarter 2023 Results on May 9, 2023

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will...

DTIL : 5.50 (-4.35%)

Business Summary

Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products primarily in the United States. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. Precision BioSciences Inc. is based in Durham, North Carolina.

See More

Key Turning Points

3rd Resistance Point 6.20
2nd Resistance Point 6.04
1st Resistance Point 5.90
Last Price 5.50
1st Support Level 5.60
2nd Support Level 5.44
3rd Support Level 5.30

See More

52-Week High 19.43
Fibonacci 61.8% 13.96
Fibonacci 50% 12.27
Fibonacci 38.2% 10.59
Last Price 5.50
52-Week Low 5.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar